Emcure Pharmaceuticals

Emcure delivered a strong Q4 FY26 with revenue of ₹2,470 croreCurrent reported value: ₹2,470 crore. No comparable prior figure is available in the source record. (+16.7Current reported value: 16.7. No comparable prior figure is available in the source record.% YoY) and EBITDA margin expansion of 130 bpsCurrent reported value: 130 bps. No comparable prior figure is available in the source record. to 19.7%Current reported value: 19.7%. No comparable prior figure is available in the source record., driven by robust international growth (+25.7%) and operating leverage. Domestic business was soft (+5.2%) due to Zuventus restructuring, but management confirmed April is back on track. Adjusted PAT grew 36% YoYCurrent reported value: 36% YoY. No comparable prior figure is available in the source record. to ₹279 crore. Guidance for FY27: low-to-mid teen revenue growth and 75-100 bps margin expansion, assuming stable macro conditions. Key growth levers include semaglutide partnership (Pista), biosimilar launches (Vasumarelic, Lenacapavir), and ADC pipeline. Risk: sustained geopolitical disruption could raise raw material costs and freight, pressuring margins if not passed through.